Ho An Thi Nhat, Shah Archan, Sagar Ala Eddin S
Department of Onco-Medicine, Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
Mediastinum. 2023 Feb 1;7:17. doi: 10.21037/med-22-39. eCollection 2023.
Central airway obstruction (CAO) is a debilitating condition with a significant impact on patient's quality of life and risk of hospitalization from respiratory failure. The causes of CAO can be both benign and malignant. Benign CAO may be idiopathic or secondary to other disease processes (infection, intubation, tracheostomy, etc.). Malignant central airway obstruction (MCAO) may occur in patients with primary lung malignancy as well as metastasis from other malignancies including renal cell, colon, and breast. In a cohort review, MCAO was found in up to 13% of patients with newly diagnosed lung cancer. The obstruction may occur either due to endoluminal disease, extrinsic compression, or a combination of both. Several bronchoscopic tools are available to manage such obstruction. Practice patterns and tools used to relieve CAO vary between institutions and may depend on physician preference, patient characteristics, emergency nature of the procedure, and nature of the obstruction. To quantify the effect and added value of such interventions, it is crucial to understand the clinical impact these interventions have on patients. The clinical impact of therapeutic bronchoscopy (TB) must then be weighed against the potential complications to justify its value. Early studies of TB for CAO included patients with both malignant and benign etiologies. The study population's heterogeneity makes it difficult to determine how TB affects clinical outcomes, as clinical outcomes are disease specific. The impact of TB for a MCAO may be different when compared to a benign CAO. Similarly, the clinical outcome of treating an idiopathic benign CAO may be different than that of a post tracheostomy airway obstruction. In this article, we will focus on the clinical outcomes of TB in MCAO. TB has been shown to have a clear impact on weaning from mechanical ventilation, dyspnea, health-related quality of life, survival and quality adjusted survival. The potential impact of TB on these outcomes should be weighed against the potential risk of complications. Understanding the factors associated with improved clinical outcomes will help physicians decide when and if TB is helpful. Future studies should focus on creating a decision analysis tool to further define decision thresholds.
中央气道阻塞(CAO)是一种使人衰弱的病症,对患者的生活质量和因呼吸衰竭住院的风险有重大影响。CAO的病因可能是良性的,也可能是恶性的。良性CAO可能是特发性的,或继发于其他疾病过程(感染、插管、气管切开术等)。恶性中央气道阻塞(MCAO)可能发生在原发性肺癌患者以及其他恶性肿瘤(包括肾细胞癌、结肠癌和乳腺癌)转移的患者中。在一项队列研究中,发现高达13%的新诊断肺癌患者存在MCAO。阻塞可能是由于腔内疾病、外部压迫或两者兼而有之。有几种支气管镜工具可用于处理此类阻塞。用于缓解CAO的实践模式和工具在不同机构之间有所不同,可能取决于医生的偏好、患者特征、手术的紧急性质以及阻塞的性质。为了量化此类干预措施的效果和附加价值,了解这些干预措施对患者的临床影响至关重要。然后必须权衡治疗性支气管镜检查(TB)的临床影响与潜在并发症,以证明其价值。早期关于TB治疗CAO的研究包括病因是恶性和良性的患者。研究人群的异质性使得难以确定TB如何影响临床结果,因为临床结果是因病而异的。与良性CAO相比,TB对MCAO的影响可能不同。同样,治疗特发性良性CAO的临床结果可能与气管切开术后气道阻塞的临床结果不同。在本文中,我们将重点关注TB治疗MCAO的临床结果。TB已被证明对机械通气脱机、呼吸困难、健康相关生活质量、生存及质量调整生存有明显影响。应将TB对这些结果的潜在影响与潜在并发症风险进行权衡。了解与改善临床结果相关的因素将有助于医生决定何时以及TB是否有用。未来的研究应专注于创建一个决策分析工具,以进一步确定决策阈值。